Abstract #3093

Enhancing Fluorine-19 Magnetic Resonance Drug Imaging: Chemical Variations in the Fluorine Side-Groups of the Immunomodulatory Drug Teriflunomide

Christian Prinz¹, Vera Martos Riaño², Tizian-Frank Ramspoth², Ludger Starke¹, Martin Neuenschwander³, Jens-Peter von Kries³, Andreas Pohlmann¹, Marc Nazaré², Thoralf Niendorf^1,4, and Sonia Waiczies¹

¹Berlin Ultrahigh Field Facility, Max Delbrück Center for Molecular Medicine, Berlin, Germany, ²Departments of Chemical Biology and Structural Biology, Leibniz-Institut fϋr Molekulare Pharmakologie (FMP), Berlin, Germany, ³Screening Unit, Leibniz-Institut für Molekulare Pharmakologie (FMP), Berlin, Germany, ⁴Experimental and Clinical Research Center, a joint cooperation between the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine, Berlin, Germany

Fluorine-19 (¹⁹F)-MR is of high relevance for the study of fluorinated drugs in vivo. Due to low drug concentrations and low numbers of fluorine atoms per molecule, the signal to be detected is very low. To address this drawback this work enhances ¹⁹F MRI of the antiinflammatory drug teriflunomide. For this purpose, derivatives of the trifluorinated drug were synthesized including modifications of the number and position of fluorine atoms in the ¹⁹F side-chains. We studied the ¹⁹F NMR characteristics and compared the SNR efficiencies of these compounds. The inhibitory activity was studied and correlated with the detectability of the compounds. By this, we can select drugs which provide a better signal than the original teriflunomide and which show an equal or even better biological activity.

This abstract and the presentation materials are available to members only; a login is required.

Join Here